Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 118

1.

Loss of PML cooperates with mutant p53 to drive more aggressive cancers in a gender-dependent manner.

Haupt S, Mitchell C, Corneille V, Shortt J, Fox S, Pandolfi PP, Castillo-Martin M, Bonal DM, Cordon-Cardo C, Lozano G, Haupt Y.

Cell Cycle. 2013 Jun 1;12(11):1722-31. doi: 10.4161/cc.24805. Epub 2013 May 8.

2.

PML isoforms IV and V contribute to adenovirus-mediated oncogenic transformation by functionally inhibiting the tumor-suppressor p53.

Wimmer P, Berscheminski J, Blanchette P, Groitl P, Branton PE, Hay RT, Dobner T, Schreiner S.

Oncogene. 2016 Jan 7;35(1):69-82. doi: 10.1038/onc.2015.63. Epub 2015 Mar 16.

PMID:
25772236
3.

Gender, mutant p53 and PML: a growing "affaire" in tumor suppression and oncogenesis.

Di Agostino S, Strano S, Blandino G.

Cell Cycle. 2013 Jun 15;12(12):1824-5. doi: 10.4161/cc.25174. Epub 2013 Jun 5. No abstract available.

4.

Promyelocytic leukemia activates Chk2 by mediating Chk2 autophosphorylation.

Yang S, Jeong JH, Brown AL, Lee CH, Pandolfi PP, Chung JH, Kim MK.

J Biol Chem. 2006 Sep 8;281(36):26645-54. Epub 2006 Jul 11.

5.

Critical role of presenilin-dependent γ-secretase activity in DNA damage-induced promyelocytic leukemia protein expression and apoptosis.

Song H, Boo JH, Kim KH, Kim C, Kim YE, Ahn JH, Jeon GS, Ryu H, Kang DE, Mook-Jung I.

Cell Death Differ. 2013 Apr;20(4):639-48. doi: 10.1038/cdd.2012.162. Epub 2013 Jan 11.

6.

Promyelocytic leukemia protein is required for gain of function by mutant p53.

Haupt S, di Agostino S, Mizrahi I, Alsheich-Bartok O, Voorhoeve M, Damalas A, Blandino G, Haupt Y.

Cancer Res. 2009 Jun 1;69(11):4818-26. doi: 10.1158/0008-5472.CAN-08-4010.

7.

Translation-dependent mechanisms lead to PML upregulation and mediate oncogenic K-RAS-induced cellular senescence.

Scaglioni PP, Rabellino A, Yung TM, Bernardi R, Choi S, Konstantinidou G, Nardella C, Cheng K, Pandolfi PP.

EMBO Mol Med. 2012 Jul;4(7):594-602. doi: 10.1002/emmm.201200233. Epub 2012 Mar 21.

8.

A cytoplasmic PML mutant inhibits p53 function.

Bellodi C, Kindle K, Bernassola F, Cossarizza A, Dinsdale D, Melino G, Heery D, Salomoni P.

Cell Cycle. 2006 Nov;5(22):2688-92. Epub 2006 Nov 15.

PMID:
17172828
9.

AXIN is an essential co-activator for the promyelocytic leukemia protein in p53 activation.

Li Q, He Y, Wei L, Wu X, Wu D, Lin S, Wang Z, Ye Z, Lin SC.

Oncogene. 2011 Mar 10;30(10):1194-204. doi: 10.1038/onc.2010.499. Epub 2010 Nov 8.

PMID:
21057547
10.

Pml and TAp73 interacting at nuclear body mediate imatinib-induced p53-independent apoptosis of chronic myeloid leukemia cells.

Liu JH, Liu CC, Yen CC, Gau JP, Wang WS, Tzeng CH.

Int J Cancer. 2009 Jul 1;125(1):71-7. doi: 10.1002/ijc.24329.

11.

PML IV/ARF interaction enhances p53 SUMO-1 conjugation, activation, and senescence.

Ivanschitz L, Takahashi Y, Jollivet F, Ayrault O, Le Bras M, de Thé H.

Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):14278-83. doi: 10.1073/pnas.1507540112. Epub 2015 Nov 2.

12.

Tyrosine kinase inhibitor, methyl 2,5-dihydromethylcinnimate, induces PML nuclear body formation and apoptosis in tumor cells.

Komura N, Asakawa M, Umezawa K, Segawa K.

Exp Cell Res. 2007 Aug 1;313(13):2753-65. Epub 2007 Apr 1.

PMID:
17585903
13.

The DNA binding property of PML/RARA but not the integrity of PML nuclear bodies is indispensable for leukemic transformation.

Liu X, Yuan H, Peres L, Chen S, Chen Z, de The H, Zhou J, Zhu J.

PLoS One. 2014 Aug 13;9(8):e104906. doi: 10.1371/journal.pone.0104906. eCollection 2014.

14.

Direct transcriptional activation of promyelocytic leukemia protein by IFN regulatory factor 3 induces the p53-dependent growth inhibition of cancer cells.

Kim TK, Lee JS, Oh SY, Jin X, Choi YJ, Lee TH, Lee Eh, Choi YK, You S, Chung YG, Lee JB, DePinho RA, Chin L, Kim H.

Cancer Res. 2007 Dec 1;67(23):11133-40.

15.

MageA2 restrains cellular senescence by targeting the function of PMLIV/p53 axis at the PML-NBs.

Peche LY, Scolz M, Ladelfa MF, Monte M, Schneider C.

Cell Death Differ. 2012 Jun;19(6):926-36. doi: 10.1038/cdd.2011.173. Epub 2011 Nov 25.

16.

β-catenin inhibits promyelocytic leukemia protein tumor suppressor function in colorectal cancer cells.

Satow R, Shitashige M, Jigami T, Fukami K, Honda K, Kitabayashi I, Yamada T.

Gastroenterology. 2012 Mar;142(3):572-81. doi: 10.1053/j.gastro.2011.11.041. Epub 2011 Dec 9.

PMID:
22155184
17.

Role of promyelocytic leukemia (PML) protein in tumor suppression.

Rego EM, Wang ZG, Peruzzi D, He LZ, Cordon-Cardo C, Pandolfi PP.

J Exp Med. 2001 Feb 19;193(4):521-29.

18.

Regulation of the PML tumor suppressor in drug-induced senescence of human normal and cancer cells by JAK/STAT-mediated signaling.

Hubackova S, Novakova Z, Krejcikova K, Kosar M, Dobrovolna J, Duskova P, Hanzlikova H, Vancurova M, Barath P, Bartek J, Hodny Z.

Cell Cycle. 2010 Aug 1;9(15):3085-99. doi: 10.4161/cc.9.15.12521. Epub 2010 Aug 26.

PMID:
20699642
19.
20.

PML regulates p53 stability by sequestering Mdm2 to the nucleolus.

Bernardi R, Scaglioni PP, Bergmann S, Horn HF, Vousden KH, Pandolfi PP.

Nat Cell Biol. 2004 Jul;6(7):665-72. Epub 2004 Jun 13.

PMID:
15195100

Supplemental Content

Support Center